Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
← catalyst calendarNCT04804553 · readout in 580 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
45
Countries
Austria, Belgium, France +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-17 | actual | When the study began enrolling |
| Primary completion | 2028-03-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Active Juvenile Psoriatic Arthritis
Interventions
- Drug: Apremilast — also filed as Otezla®
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants who Achieve American College of Rheumatology Pediatric (ACR) Pedi 30 Response at Week 16
measured Baseline to Week 16
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed